Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVD±R in Relapsed/Refractory DLBCL
NCT04021992Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Primary endpoint: Overall Response Rate at 4 years. Status: unknown.
02
Drugs
gemcitabinevinorelbinepegylated liposomal doxorubicinrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04021992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021992.